ALK-positive NSCLC status should be known prior to initiation of Alunbrig therapy. A validated ALK assay is necessary for the selection of ALK positive NSCLC patients (see section 5.1). ALK-positive NSCLC status should be performed by laboratories with demonstrated proficiency in the specific technology being utilised. The gene discussed is ALK; the disease is non-small cell lung carcinoma.